Antibiotic price drop could stop millions from developing tuberculosis: New agreement secures 66% reduction in cost of rifapentine, which prevents ‘latent’ TB from becoming active. Available to those who could afford it, it has, until now, been “completely unaffordable” in developing countries.
No comments:
Post a Comment